Pan-European private equity investor Bridgepoint Growth has taken a stake in Swedish medical dermatology group Diagnostiskt Centrum Hud (DCH).
Financial terms have not been disclosed.
Headquartered in Stockholm, DCH was founded in 2012 to address the untapped demand for high quality medical dermatology treatments. The market is underpinned by structural growth drivers, including an ageing population and an increase in the incidence of skin diseases such as skin cancers.
DCH focuses on treating melanoma, psoriasis and other severe dermatology conditions.
Today DCH operates six clinics across four Swedish cities and is the clear market leader in Sweden.
“We are very impressed by DCH’s successful expansion to-date creating the leading dermatology provider focused on clinical excellence and high customer satisfaction thanks to its having the best dermatologists. We look forward to supporting the DCH team in its next phase of expansion” said Ann Dahlman, partner at Bridgepoint Growth responsible for its investment activities in the Nordic region.
Advisors for Bridgepoint were Vinge (legal), KPMG (financial and tax), Roland Berger (commercial). For DCH they were AG Advokat (legal) and GT (financial and tax).